While all our patients received standard pre-medication with dexamethasone, we did not see a hyperglycemia rate higher than that used in the SOLAR-1 trial, which combined alpelisib with fulvestrant in patients with advanced PIK3CA-mutated hormone-positive breast cancer (2). The gene discussed is PIK3CA; the disease is Hyperglycemia.